Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
CTHCF$0.72-0.14(-16.20%)CoTec Holdings Corp. Comments on Share Trading[3:47:00 PM ET]ECRFF$0.13-0.01(-6.39%)Cartier Files on SEDAR+ the NI 43-101 Technical Report of the updated Preliminary Economic Assessment for the Cadillac Project: After-tax NPV5% of C$1.0 billion and after-tax IRR of 26.6% at US$3,600/oz gold price[3:17:02 PM ET]SRXH$1.01-0.01(-0.50%)SRX Global Provides Update on Balance Sheet and Share Buyback[3:16:00 PM ET]YMMCF$0.17-0.03(-15.00%)Video - CEO Clips: Exploring the Potential for a Major Copper-Gold Discovery in Yukon[3:06:00 PM ET]OZBKF$0.17-0.02(-11.46%)Valkea Approves Advance Notice Policy and Grants Stock Options[3:05:00 PM ET]CCL$28.87+0.02(+0.09%)Royal Princess Emerges from Drydock with New Sanctuary Collection Princess Cruises reveals a series of enhancements aboard Royal Princess, as the 3,595-guest ship emerges from a two-week drydock in Singapore. The...[3:00:00 PM ET]KFFB$5.36-0.04(-0.69%)Kentucky First Federal Bancorp Announces Payment of Quarterly Dividend[2:59:17 PM ET]ADMT$0.07+0.01(+8.33%)ADM Tronics Closes First Two Tranches of Private Placement and Strengthens Board of Directors[2:45:00 PM ET]DOV$207.43-2.94(-1.40%)Dover Announces Upsize of Its Tender Cap and Extension of Expiration Date of Previously Announced Offer to Purchase for Cash Certain of Its Outstanding Debt Securities[2:38:37 PM ET]EONR$0.31-0.06(-15.65%)EON Resources Inc. Outlines Strategic Plan to Transition Development Potential into Producing Value[2:30:00 PM ET]EIX$58.81-0.57(-0.96%)Record Pace of Eaton Fire Claims for SCE Program Continues Ahead of Nov. 30 Deadline[2:30:00 PM ET]UNF$255.59-1.77(-0.69%)UniFirst Declares Increased Cash Dividends[2:25:57 PM ET]

AGIO · NASDAQ

Agios Pharmaceuticals, Inc.

$30.24 -7.00 (-18.80%)

Company overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat), an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes for the treatment of hemolytic anemias, and AG-946, which is in Phase I clinical studies for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.8B
Employees
486
Headquarters
Cambridge, MA
Website
agios.com
CEO
Brian Goff
Listed
July 24, 2013
P/E
-4.21
Dividend yield
0.00%

Company financials

Revenue
$66M
Gross profit
$54.2M
Operating income
-$476M
EBITDA
-$470M
Net income
-$423M
EPS
-$7.25
Total assets
$1.2B
Total debt
$35.7M
Gross margin
82.07%
Net margin
-639.84%
Earnings yield
-23.77%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

23.5028.8434.1939.5444.88
AGIO 1D NASDAQ O38.23H38.69L36.76C37.23-0.89 (-2.33%)Vol984.41K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
AGIOAgios Pharmaceuticals, Inc. Stock news Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade) Seeking Alpha
AGIOAgios Pharmaceuticals, Inc. Press release Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA GlobeNewswire
AGIOAgios Pharmaceuticals, Inc. Stock news Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks Investment Research
AGIOAgios Pharmaceuticals, Inc. Press release A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a... PR Newswire
AGIOAgios Pharmaceuticals, Inc. Press release Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET GlobeNewsWire
AGIOAgios Pharmaceuticals, Inc. Stock news AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know Zacks Investment Research
AGIOAgios Pharmaceuticals, Inc. Stock news Agios' Growth Story Hinges on Mitapivat's Commercial Expansion Zacks Investment Research
LMNR Stock news Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Benzinga
AGIOAgios Pharmaceuticals, Inc. Stock news Bank of New York Mellon Corp Invests $7.37 Million in Agios Pharmaceuticals, Inc. $AGIO Defense World
AGIOAgios Pharmaceuticals, Inc. Stock news Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel Seeking Alpha
AGIOAgios Pharmaceuticals, Inc. Stock news Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO Defense World
AGIOAgios Pharmaceuticals, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO GlobeNewsWire
AGIOAgios Pharmaceuticals, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO PRNewsWire
AGIOAgios Pharmaceuticals, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO GlobeNewsWire
AGIOAgios Pharmaceuticals, Inc. Stock news Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks Investment Research
AGIOAgios Pharmaceuticals, Inc. Stock news AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program Zacks Investment Research
AGIOAgios Pharmaceuticals, Inc. Stock news Agios Reports Neutral Sickle Cell Data, Decides To Stop Development Benzinga
AGIOAgios Pharmaceuticals, Inc. Stock news Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Benzinga
AGIOAgios Pharmaceuticals, Inc. Stock news Agios Pharma to discontinue sickle cell disease treatment development Reuters
AGIOAgios Pharmaceuticals, Inc. Press release Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease GlobeNewsWire
See more
FAQ

Questions about Agios Pharmaceuticals, Inc.

What does Agios Pharmaceuticals, Inc. do?
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat), an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes for the treatment of hemolytic anemias, and AG-946, which is in Phase I clinical studies for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
What is AGIO's market cap?
Agios Pharmaceuticals, Inc. (AGIO) is a listed stock with a live quote. The latest market cap on this page is $1.8B.
Where is Agios Pharmaceuticals, Inc. headquartered?
Agios Pharmaceuticals, Inc. is headquartered in Cambridge, MA.
How do I get AGIO news from the API?
Call GET /v1/news?tickers=AGIO. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does AGIO news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for AGIO, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the AGIO price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs